Key result
Oral anticoagulation is preferred for cardioembolism in atrial fibrillation, while antiplatelet therapy is favored in other settings due to varying hemorrhage risks.
Why the study?
How do different antithrombotic therapies compare in preventing recurrent stroke and minimizing hemorrhage risk across various stroke etiologies?
How do different antithrombotic therapies compare in preventing recurrent stroke and minimizing hemorrhage risk across various stroke etiologies?
The choice of antithrombotic therapy for stroke prevention should be tailored to the underlying etiology, balancing the reduction in stroke risk against the risk of hemorrhage.
No takes yet. Share an insight, caveat, or question.
Etiology-specific antithrombotic selection may guide secondary prevention; leaves open prospective validation across stroke subtypes.
Chong et al. (2005) conducted a review in Stroke prevention. Anticoagulation and antiplatelet therapy was evaluated. Oral anticoagulation is preferred for cardioembolism in atrial fibrillation, while antiplatelet therapy is favored in other settings due to varying hemorrhage risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: